FI82253C - Foerfarande foer framstaellning av farmakologiskt vaerdefulla tigogencellubiocider. - Google Patents

Foerfarande foer framstaellning av farmakologiskt vaerdefulla tigogencellubiocider. Download PDF

Info

Publication number
FI82253C
FI82253C FI842935A FI842935A FI82253C FI 82253 C FI82253 C FI 82253C FI 842935 A FI842935 A FI 842935A FI 842935 A FI842935 A FI 842935A FI 82253 C FI82253 C FI 82253C
Authority
FI
Finland
Prior art keywords
tigogenin
cholesterol
anomer
mixture
cellubicide
Prior art date
Application number
FI842935A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI842935L (fi
FI82253B (fi
FI842935A0 (fi
Inventor
Malinow Rene M
Original Assignee
Oregon Medical Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Medical Res Found filed Critical Oregon Medical Res Found
Publication of FI842935A0 publication Critical patent/FI842935A0/fi
Publication of FI842935L publication Critical patent/FI842935L/fi
Publication of FI82253B publication Critical patent/FI82253B/fi
Application granted granted Critical
Publication of FI82253C publication Critical patent/FI82253C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
    • A61M15/0015—Details of inhalators; Constructional features thereof with inhalation check valves located upstream of the dispenser, i.e. not traversed by the product
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
    • A61M15/0016—Details of inhalators; Constructional features thereof with inhalation check valves located downstream of the dispenser, i.e. traversed by the product
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0086—Inhalation chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Cephalosporin Compounds (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
FI842935A 1984-04-20 1984-07-23 Foerfarande foer framstaellning av farmakologiskt vaerdefulla tigogencellubiocider. FI82253C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60229884 1984-04-20
US06/602,298 US4602005A (en) 1982-05-17 1984-04-20 Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis

Publications (4)

Publication Number Publication Date
FI842935A0 FI842935A0 (fi) 1984-07-23
FI842935L FI842935L (fi) 1985-10-21
FI82253B FI82253B (fi) 1990-10-31
FI82253C true FI82253C (fi) 1991-02-11

Family

ID=24410793

Family Applications (2)

Application Number Title Priority Date Filing Date
FI842935A FI82253C (fi) 1984-04-20 1984-07-23 Foerfarande foer framstaellning av farmakologiskt vaerdefulla tigogencellubiocider.
FI900531A FI87792C (fi) 1984-04-20 1990-02-02 Tigogenin-cellubiosid-okta-acetat

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI900531A FI87792C (fi) 1984-04-20 1990-02-02 Tigogenin-cellubiosid-okta-acetat

Country Status (16)

Country Link
US (1) US4602005A (enExample)
EP (1) EP0159431B1 (enExample)
JP (1) JPS60224697A (enExample)
KR (1) KR940002114B1 (enExample)
AT (1) ATE42959T1 (enExample)
AU (1) AU580005B2 (enExample)
CA (1) CA1246544A (enExample)
DE (1) DE3478114D1 (enExample)
DK (2) DK165839C (enExample)
ES (1) ES8601233A1 (enExample)
FI (2) FI82253C (enExample)
HU (1) HUT37802A (enExample)
IE (1) IE58015B1 (enExample)
NO (1) NO842990L (enExample)
NZ (1) NZ208961A (enExample)
ZA (1) ZA845690B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US4865850A (en) * 1986-09-08 1989-09-12 See/Shell Biotechnology, Inc. Dietary fat reduction
US5010185A (en) * 1989-06-13 1991-04-23 Pfizer Inc. Processes for tigogenin beta-cellobioside
US5091192A (en) * 1990-01-16 1992-02-25 Natur-All Systems, Inc. Bile salts permanently bound to insoluble cellulose as a dietary supplement
ATE165367T1 (de) * 1991-10-04 1998-05-15 Procter & Gamble Cholesterinsenkende verbindungen und verfahren zu ihrer herstellung
CA2079544A1 (en) * 1991-10-04 1993-04-05 Adam Weislaw Mazur Cholesterol lowering compounds
HUT67035A (en) * 1991-11-25 1995-01-30 Pfizer New process for the production of steroidal glycosides derivatives
US5294703A (en) * 1992-05-01 1994-03-15 Eastman Kodak Company Process for preparing α-D-cellobiose octaacetate
SK158394A3 (en) * 1992-06-26 1995-05-10 Pfizer Steroidal glycosides
AU4044293A (en) * 1992-06-26 1994-01-24 Pfizer Inc. Process for steroidal peracyl glycosides
FI946081A7 (fi) * 1992-06-26 1994-12-23 Pfizer Steroidaalinen beta-0-sellobiosidihepta-alkanoaattimenetelmä
US5530107A (en) * 1992-10-15 1996-06-25 Pfizer Inc. Method for making steroidal peracyl glycosides
EP0696292A1 (en) * 1993-04-28 1996-02-14 Pfizer Inc. Spirostanyl glycosidal crystalline monohydrate
US5502038A (en) * 1993-06-21 1996-03-26 Medical Research Foundation Of Oregon Cholesterol sequestrant glycosides that inhibit intestinal cholesterol absorption
AU7250694A (en) * 1993-06-25 1995-01-17 Biosphere Technologies Inc. Dietary supplement incorporating beta-sitosterol and pectin
ES2074006B1 (es) * 1993-07-05 1996-03-16 Pfizer Glicosidos esteroidales para tratar hipercolesterolemia.
AU7948494A (en) * 1993-12-28 1995-07-17 Pfizer Inc. Steroidal glycosides
US5607841A (en) * 1994-06-20 1997-03-04 Lipinski; Boguslaw Preparation and proteolytic degradation of a macromolecular protein complex from fibrinogen
US5807834A (en) * 1994-09-20 1998-09-15 Pfizer Inc. Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor
US6150336A (en) * 1995-05-29 2000-11-21 Pfizer Inc. Steroidal glycosides
US5698527A (en) * 1995-08-08 1997-12-16 Merck & Co., Inc. Steroidal glycosides as antihyperlipidemic agents
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
GB9923076D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
KR101092050B1 (ko) * 1998-03-26 2011-12-12 파이토팜 피엘씨 알츠하이머병을 치료하기 위한 스밀라게닌 및 안주로게닌-ｄ
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923077D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
JP4711600B2 (ja) * 2001-01-26 2011-06-29 シェーリング コーポレイション シトステロール血症の処置のための置換アゼチジノン化合物の使用
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
EP1785144A3 (en) * 2001-01-26 2007-05-23 Shering Corporation Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
SI1413331T1 (sl) * 2001-01-26 2008-02-29 Schering Corp Kombinacije fenofibrata peroksisomskega proliferator aktivirajocega receptorja (PPAR) z ezetimib zaviralcem absorpcije sterola za vaskularne indikacije
US20020147184A1 (en) * 2001-01-26 2002-10-10 Schering Corporation Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
CA2434488A1 (en) * 2001-01-26 2002-08-01 Harry R. Davis Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
DK1385548T3 (da) * 2001-01-26 2007-09-10 Schering Corp Kombinationer af sterolabsorptionsinhibitor(er) med (et eller flere) kardiovaskulære midler til behandling af vaskulære tilstande
GB0107822D0 (en) * 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
WO2002096415A2 (en) * 2001-05-25 2002-12-05 Schering Corporation Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
ATE411018T1 (de) * 2001-09-21 2008-10-15 Schering Corp Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
US7132415B2 (en) * 2001-09-21 2006-11-07 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US20050130948A1 (en) * 2002-03-27 2005-06-16 Daryl Rees Therapeutic methods and uses of sapogenins and their derivatives
CN102727501A (zh) * 2002-03-27 2012-10-17 菲特法姆股份有限公司 皂角苷配基及其衍生物的用途
CA2504878A1 (en) * 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorption inhibitors for the treatment of demyelination
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CN100439361C (zh) 2003-03-07 2008-12-03 先灵公司 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
CN1756755A (zh) * 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
EP1680189A2 (en) * 2003-11-05 2006-07-19 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
WO2005063790A1 (en) * 2003-12-31 2005-07-14 Council Of Scientific & Industrial Research Isolation of tigogenin pentaglycoside from chlorophytum nimonii
US7160866B2 (en) 2004-03-22 2007-01-09 Council Of Scientific And Industrial Research Isolation of tigogenin pentaglycoside from Chlorophytum nimonii

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2759171A1 (de) * 1977-12-31 1979-07-12 Roecar Holdings Nv Arzneimittel mit wirkung als prostaglandinsynthetaseninhibitor
DE2926463A1 (de) * 1978-07-05 1980-01-24 Roecar Holdings Nv Spiroketaline und ihre verwendung
US4260603A (en) * 1979-01-02 1981-04-07 Pegel Karl H Sterol glycoside with activity as prostaglandin synthetase inhibitor
US4242502A (en) * 1979-04-20 1980-12-30 United States Of America Enhancement of cholesterol combining properties of saponins
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US4602003A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia

Also Published As

Publication number Publication date
DK166213B (da) 1993-03-22
NO842990L (no) 1985-10-21
EP0159431A3 (en) 1986-01-08
EP0159431A2 (en) 1985-10-30
ES534553A0 (es) 1985-11-16
DK361084A (da) 1985-10-21
FI842935L (fi) 1985-10-21
FI82253B (fi) 1990-10-31
DK361084D0 (da) 1984-07-23
AU580005B2 (en) 1988-12-22
EP0159431B1 (en) 1989-05-10
NZ208961A (en) 1988-01-08
ES8601233A1 (es) 1985-11-16
AU3097784A (en) 1985-10-24
JPS60224697A (ja) 1985-11-09
DK165839C (da) 1993-06-21
FI87792B (fi) 1992-11-13
DK14892A (da) 1992-02-06
DK166213C (da) 1993-08-16
DK14892D0 (da) 1992-02-06
ATE42959T1 (de) 1989-05-15
FI842935A0 (fi) 1984-07-23
DE3478114D1 (en) 1989-06-15
JPH0456840B2 (enExample) 1992-09-09
FI87792C (fi) 1993-02-25
ZA845690B (en) 1986-03-26
FI900531A0 (fi) 1990-02-02
KR850007432A (ko) 1985-12-04
IE841904L (en) 1985-10-20
IE58015B1 (en) 1993-06-16
HUT37802A (en) 1986-02-28
CA1246544A (en) 1988-12-13
DK165839B (da) 1993-01-25
KR940002114B1 (ko) 1994-03-17
US4602005A (en) 1986-07-22

Similar Documents

Publication Publication Date Title
FI82253C (fi) Foerfarande foer framstaellning av farmakologiskt vaerdefulla tigogencellubiocider.
US5369096A (en) Glycolipid derivatives
US6017892A (en) Method for accelerating marrow cell proliferation
JP3074733B2 (ja) 脂肪乳剤
EP0237051A2 (en) Prodrug compounds, process for the preparation thereof and sustained release preparation comprising the same
JPH07501341A (ja) 細胞接着阻害剤としての置換されたラクトースおよびラクトサミン誘導体
JP2930245B2 (ja) １，２，３，４―テトラヒドロ―９―アクリジナミンの誘導体
EP0488513B1 (en) Use of dioxabicyclo [3.3.0]octane derivatives for the manufacture of a medicament for inhibiting the metabolism of cholesterol.
EP1172107B1 (en) Drugs containing sulfopyranosylacylglycerol derivatives
JPS62258366A (ja) 置換ピリミジンアミド
CH683427A5 (fr) Composé d'isoquinoléine comme agents de blocage neuromusculaire.
KR100195421B1 (ko) 6-아미노옥타히드로인돌리진트리올유도체
US4960595A (en) Lipid membrane structures
JPH1067656A (ja) 細胞接着抑制剤
MC2164A1 (fr) Steroides
JP2647882B2 (ja) 鮫組織から単離した有効成分
EP0082818A1 (fr) Procédé pour l'obtention de lipides d'origine humaine et du lacto-N-norhexaosyl ceramide
CA2364446C (en) Novel immunosuppressive agent
KR20060028630A (ko) 이노시톨 폴리포스페이트 유도체 및 그의 사용 방법
WAGO Antiatherosclerotic and anticoagulant activity of cerebroside sulfate
US6136800A (en) 17-Difluoromethylene-estratrienes
US6057308A (en) Remedy or preventive for hyperlipemia
KR20000016565A (ko) 폴리올 숙시네이트 및 이의 약제학적 제제
KR20010012764A (ko) 2,3-디히드로벤조푸란 유도체
EP0510197A1 (en) Fat emulsion

Legal Events

Date Code Title Description
MM Patent lapsed

Owner name: MEDICAL RESEARCH FOUNDATION OF OREGON